Xpress Biologics


Xpress Biologics is a Contract Development and Manufacturing Organization (CDMO) specialized in the development of manufacturing processes for the production of Biologics (recombinant proteins, antibody fragments and DNA) for therapeutic, vaccine and diagnostic applications. The services proposed by Xpress Biologics include the development of microbial expression cell lines, the development of the upstream and downstream process including the development of the in process and product quality controls. Additional services as the realization of the stress studies and the development of the drug substance formulation are also proposed. The production of R&D, GLP/HQ and, starting in Q2 2023, GMP grade material is proposed.